ArcticZymes - enzymes from Norway

Osavuosiraportti

https://newsweb.oslobors.no/message/530774

Highlights from Q1 2021

  • ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million)

  • Coronavirus-related sales are estimated at NOK 16.5 million in Q1 2021 (NOK 3.8 million in Q1 2020)

  • Gross profit improved to NOK 39.9 million with 99% margin (Q1 2020: NOK 18.5 Million)

  • AZT delivered a positive EBITDA of NOK 25.8 million (Q1 2020: NOK 9.0 million)

  • Cash-flow for Q1 was positive NOK 23.2 million (Q1 2020: NOK 4.4 million) giving a cash balance of NOK 163.3 million (Q1 2020: NOK 35.7 million)

  • Successfully upscaled the SAN HQ production process

3 Likes